Ten experts on NIH C-19 panel have ties to companies involved in coronavirus treatment

follow the money

Ten experts on a NIH COVID-19 panel have ties to companies involved in coronavirus treatment

Eight members of NIH’s COVID-19 Treatment Guidelines Panel list financial ties to Gilead Sciences, whose COVID-19 drug remdesivir has been touted by Dr. Anthony Fauci. [Two other members are tied to Merck research.]

By Nicholas Ballasy

Members of the National Institutes of Health’s COVID-19 Treatment Guidelines Panel have financial ties to a company behind clinical trials of a drug to treat coronavirus, as well as to another large pharmaceutical company involved with developing a COVID-19 vaccine.

According to the NIH, members of the panel include U.S. physicians, statisticians, and other experts who are developing treatment guidelines on COVID-19 “intended for healthcare providers.”

A total of eight panel members list a financial relationship with Gilead Sciences on the panel’s Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics document: Judith Aberg, MD, Adaora Adimora, MD, Jason Baker, MD, Roger Bedimo, MD, Eric Daar, MD, David V. Glidden, PhD, Susanna Naggie, MD, and Pablo Tebas, MD.

The U.S. has reportedly bought almost all of Gilead Sciences’ supply of the COVID-19 drug remdesivir. The company announced on June 1 the results of a phase 3 clinical trial of the drug in patients with moderate COVID-19.

On Monday, Gilead applied for FDA approval of remdesivir, which has been available for emergency use with patients hospitalized with severe cases of COVID-19.

“The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery,” Dr. Anthony Fauci (pictured left), director of the National Institute of Allergy and Infectious Diseases (NIAID), announced back on April 29 in an interview with NBC News, citing results of a large international study sponsored by his NIAID.

“And all of the other trials that are taking place now have a new standard of care,” said Fauci.

Dr. William O’Neill (pictured right), a cardiologist and Medical Director at the Henry Ford Health System in Detroit, Mich., told Just the News contributor Sharyl Attkisson in an interview for her news program “Full Measure” that he is less impressed with remdesivir.

“There is a lot of hype for the drug,” said O’Neil, adding that he sees “no big benefit” to remdesivir after reading medical journal reports on it.

Andrew T. Pavia, MD and Rajesh Gandhi, MD list Merck on the NIH disclosure form.

Merck is currently conducting clinical trials for a COVID-19 vaccine. Merck’s target date for a licensed COVID-19 vaccine is early 2021, according to recent congressional testimony.

The COVID-19 treatment guidelines are “based on published and preliminary data and the clinical expertise of the panelists, many of whom are frontline clinicians caring for patients during the rapidly evolving pandemic.”

Fauci is not listed on the NIH financial disclosure form.

_________

Related News

WSJ reports there are indicators of decreases in new coronavirus cases in much of the U.S.

Russian President Vladimir Putin says country has approved world’s first coronavirus vaccine

_________

THE FACTS INSIDE OUR REPORTER’S NOTEBOOK

Links

*********

(TLB) published this article with permission of John Solomon at Just the News

Some emphasis and pictorial content added by (TLB)

Click Here to read about the staff at Just the News

••••

••••

Stay tuned to …

••••

The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)

••••

Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.

••••

Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.

••••

Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.

Be the first to comment

Leave a Reply

Your email address will not be published.


*